Enjoy complimentary customisation on priority with our Enterprise License!
The global oligonucleotide synthesis market size is estimated to grow by USD 3.37 billion, at a CAGR of 13.54% between 2023 and 2028. The growth of the market depends on several factors, including the increasing research activities in the pharmaceutical and biotechnology sectors, and increasing use of oligonucleotides as therapeutic and diagnostic tools, and the emergence of technological innovations in oligonucleotide synthesis. Challenges such as regulatory issues associated with oligonucleotide therapeutics, diversity in oligonucleotide molecules, and challenges in effective oligonucleotide delivery might restrain the growth of the market. Nevertheless, factors such as increasing focus on R&D of new oligonucleotide therapeutics, increasing research funding, and rise in demand for low-cost and high-throughput oligonucleotide synthesis is key trend shaping the market.
To learn more about this report, Download Report Sample
The market share growth by the PCR primers segment will be significant during the forecast period. PCR primers are short oligonucleotide sequences that are designed to bind to specific target DNA sequences and initiate the amplification process in PCR reactions. They serve as essential components in PCR-based applications, including gene expression analysis, DNA sequencing, mutation detection, and genotyping.
Get a glance at the market contribution of various segments Download PDF Sample
The PCR primers segment was valued at USD 499.37 million in 2018. The demand for PCR primers is particularly high in high-throughput applications, such as large-scale genotyping or DNA sequencing projects. Oligonucleotide synthesis companies are equipped to handle the synthesis of a large number of PCR primers simultaneously to support these high-throughput applications. The growth of the PCR primers segment in the market is projected to benefit from these factors over the forecast period.
Oligonucleotide synthesis finds significant applications in pharmaceutical and biotechnology companies, particularly in the development of oligonucleotide therapeutics. These companies are actively researching various oligonucleotide-based treatments, including siRNA therapy, antisense oligonucleotide therapy, miRNA therapy, aptamer therapy, and CpG oligonucleotide therapy. Regulatory approvals from agencies like the FDA and EMA have spurred the focus on oligonucleotide therapies, making pharmaceutical and biotech companies major users of oligonucleotide synthesis products and services. The rising number of drug-related research and clinical trials globally is expected to drive market growth in the coming years.
For more insights about the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominates the regional market, with the US leading the regional market. The adoption of synthetic nucleic acids for research, therapeutic applications, and diagnosis is driven by the presence of a leading market. Market players in the US are using advanced technologies and methodologies to meet the growing demand for oligo nucleotides.
Additionally, the growing approval of oligonucleotide therapies by the US FDA has eased the commercial availability of these treatments in North America. Most oligonucleotide therapies are focused on the treatment of rare diseases such as Homozygous Familial Hypercholesterolemia and DMD. In other countries of North America, including Canada, oligonucleotide therapies such as Exondys 51 for DMD are under clinical trials. The growing prevalence of rare diseases has increased the demand for oligonucleotide therapies in the region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Ajinomoto Bio Pharma. , Alnylam Pharmaceuticals Inc., Amgen Inc., Ansa Biotechnologies, Bio Synthesis Inc, Biogen Inc., Biotage AB, Danaher Corp., Eurofins Scientific SE, General Electric Co., Ionis Pharmaceuticals Inc., Kaneka Corp., LGC Science Group Holdings Ltd., Merck KGaA, Mettler Toledo International Inc., QIAGEN NV, Sarepta Therapeutics Inc., Synbio Technologies, Syngene International Ltd., and Thermo Fisher Scientific Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market drives innovation in genetic research and therapeutics. Utilizing techniques like solid-phase synthesis, it synthesizes precise nucleotide chains, including adenine, cytosine, guanine, thymine, and uracil, crucial components of RNA and DNA. Amidst ambitious genome projects, oligonucleotides play a pivotal role in elucidating genetic intricacies and developing targeted therapeutic drugs for ailments like cystic fibrosis. Advanced vector technologies enable efficient delivery in gene therapy and antisense therapy, revolutionizing medical treatments. Oligonucleotides, composed of a phosphate group, sugar molecule (either deoxyribose or ribose), and a nitrogenous base, hold promise in interference RNA, offering potential solutions to various genetic disorders. As demand surges for precise molecular tools, the market remains a cornerstone in scientific advancement and therapeutic innovation.
Increasing use as therapeutic and diagnostic tools is the key factor driving the market. Genetic diagnosis of targets, peptides, small molecules, and proteins are some applications where oligonucleotide biosensors are considerably used. This has broadened the applications of oligonucleotides in the healthcare and medical sectors, specifically for in vitro diagnosis of infectious diseases such as respiratory tract infections (including tuberculosis and influenza), hepatitis, and encephalitis, using PCR amplification and microarray-based methodologies.
Additionally, the high prevalence of infectious diseases has surged the demand for performing DNA microarray, transcription-mediated amplification (TMA), and nucleic acid sequence-based amplification, which is used in in vitro diagnosis of these diseases. This has surged the demand for oligonucleotide synthesis in diagnostic laboratories. Further, the market is observing a rising demand from the pharmaceutical and biotechnology sectors owing to the increasing commercial approval of oligonucleotide therapies by authorities such as the US FDA and EMA. Thus, the growing commercial availability of oligonucleotide therapies is expected to drive market growth during the forecast period.
The rise in demand for low-cost and high-throughput oligonucleotide synthesis is a primary trend in the market. The large-scale production of desired gene sequences at a lower cost could contribute to rapid progress in both fundamental and applied biological research. The costs of gene synthesis are directly proportional to the cost since genetic material is made from oligonucleotides. The reduction of the process costs makes it possible to generate a more efficient set of gene data. Hence, there is an increasing demand for techniques and technologies that allow the synthesis of oligonucleotides and their assembly into larger DNA constructs with increased sequence fidelity at a reduced cost.
Additionally, automated methods have become more common, such as the synthesis of oligonucleotides with Computer Controlled Instruments for Solid Phase Support. The major costs of gene synthesis are also associated with reagents that are applied. Hence, there is an increasing demand for approaches and tools that reduce reagent consumption, enhance the robustness and accuracy of the gene assembly process, and increase throughput in oligonucleotide synthesis. Such factors are expected to drive the growth of the market during the forecast period.
The diversity in oligonucleotide molecules is a major challenge that impedes market growth. Oligonucleotides are larger molecules than traditional small molecules used in therapeutics. Effective uptake of oligonucleotides in a targeted location decides the success of drug candidates. However, the diversity within the classes of therapeutics in terms of the size of the molecule and range of chemical modification necessitates careful consideration before nucleic acid synthesis.
Furthermore, compared to complex molecules, fewer target sites allow small molecules to be modified in a restricted manner. For this reason, to address the different mechanisms of action and features of these molecules, all oligonucleotide types must be considered carefully. The complexity and diversity in oligonucleotide molecules increase the propensity for performance failure of drug candidates due to undetected impurity and toxicity. Thus, non-compliance with regulatory requirements can negatively impact drug manufacturers. This trend is expected to hinder the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. The market research and growth report focuses on adoption rates in different regions based on penetration. Furthermore, the market growth and forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market growth analysis research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2022 for the following segments
You may also interested in below market reports:
The market is witnessing remarkable growth, driven by advancements in solution-phase synthesis and polymerase chain reaction (PCR) techniques. Technologies like CRISPR have revolutionized genetic testing and gene therapies, particularly in addressing diseases such as cancer and Charcot-Marie-Tooth disease caused by genetic mutations. Companies like EnPlusOne Biosciences and Ajinomoto Bio-Pharma Services are at the forefront, offering synthesized oligonucleotides and contract services for oligonucleotide-based drugs and therapies. Antisense oligonucleotide drugs like Vitravene are gaining traction in clinical studies, showcasing the potential of oligonucleotide-based therapies. Providers offer services such as oligonucleotide modification, purification, and labeling to meet the demands of molecular testing and analytical testing. The market is propelled by artificial gene synthesis and enzymatic DNA synthesis, paving the way for innovative gene therapies and protein synthesis.
Further, the market is witnessing substantial growth with advancements in diagnostics and genetic research. Technologies like polymerase chain reactions (PCR) play a crucial role in amplifying DNA sequences for various applications, including diagnosing genetic disorders such as Down syndrome. Targeted therapies using antisense oligonucleotide drug are gaining momentum, particularly for conditions linked to specific genes like the IGHMBP2 gene. Contract service providers like Creative Biolabs are instrumental in offering oligonucleotide synthesis providers and purification services, including labeling modifications and backbone modifications, to meet diverse research needs. Cutting-edge techniques such as polyacrylamide gel electrophoresis and RNA-induced silencing complex are enhancing oligonucleotide purification technology, driving innovation in molecular biology and therapeutics.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
183 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 13.54% |
|
Market Growth 2024-2028 |
USD 3.37 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
13.32 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 40% |
|
Key countries |
US, Canada, Germany, China, and Japan |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Agilent Technologies Inc., Ajinomoto Bio Pharma. , Alnylam Pharmaceuticals Inc., Amgen Inc., Ansa Biotechnologies, Bio Synthesis Inc, Biogen Inc., Biotage AB, Danaher Corp., Eurofins Scientific SE, General Electric Co., Ionis Pharmaceuticals Inc., Kaneka Corp., LGC Science Group Holdings Ltd., Merck KGaA, Mettler Toledo International Inc., QIAGEN NV, Sarepta Therapeutics Inc., Synbio Technologies, Syngene International Ltd., and Thermo Fisher Scientific Inc. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the market forecast period. |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.